Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $30.55.

Several research firms have weighed in on ROIV. Piper Sandler lifted their target price on Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Weiss Ratings cut shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Finally, Citigroup raised their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $28.56 on Friday. Roivant Sciences has a twelve month low of $10.58 and a twelve month high of $30.33. The stock has a market cap of $20.44 billion, a price-to-earnings ratio of -24.41 and a beta of 1.14. The firm’s 50 day moving average price is $28.34 and its two-hundred day moving average price is $24.25.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $26.47, for a total value of $8,985,003.27. Following the transaction, the insider owned 19,148,664 shares in the company, valued at $506,865,136.08. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. This trade represents a 10.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 5,085,398 shares of company stock worth $139,215,946 over the last 90 days. 10.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. UBS Group AG grew its stake in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Morgan Stanley grew its stake in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $112,750,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.